Johnson & Johnson Says IMAAVY Showed Rapid And Durable Anemia Improvement In wAIHA, A Disease With No FDA-Approved Therapies

Johnson & Johnson

Johnson & Johnson

JNJ

0.00
  • Patients in the IMAAVY 30 mg/kg treatment groupa achieved statistically significant durable hemoglobin responseb, with mean hemoglobin improvement of at least 1 g/dL as early as Week 1c 
  • More patients treated with IMAAVY experienced improvement in fatigued and corticosteroid dose reductionse
  • IMAAVY is designed to target pathogenic immunoglobulin G (IgG) autoantibodies in warm autoimmune hemolytic anemia while preserving immune function
  • Pivotal results will be presented at EHA 2026
This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.